Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis

Salaheldin, Mohamed; Aly, Heba; Lau, Louis Ho Shing; Afify, Shimaa; Kassas, Mohamed El

doi:10.3390/diagnostics13162631

Cited by 9 publications

(5 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the relationship between MASLD and HCC is complex and requires further studies. 49 Additionally, some patients with MASLD or MASH who develop HCC may also have coexisting viral hepatitis (such as hepatitis B or C) or other metabolic diseases, which can mask the actual estimation of MASLDrelated HCC. With the increasing prevalence of MASLD and MASH, the incidence of related HCC is expected to continue to rise.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

El-Kassas,

Awad,

Elbadry

et al. 2024

Semin Liver Dis

Self Cite

View full text Add to dashboard Cite

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is increasing globally, creating a growing public health concern. However, this disease is often not diagnosed, and accurate data on its epidemiology are limited in many geographical regions, making it challenging to provide proper care and implement effective national plans. To combat the increasing disease burden, screening and diagnosis must reach a significant number of high-risk subjects. Addressing MASLD as a healthcare challenge requires a multidisciplinary approach involving prevention, diagnosis, treatment, and care, with collaboration between multiple stakeholders in the healthcare system. This approach must be guided by national and global strategies, to be combined with efficient models of care developed through a bottom-up process. This review article highlights the pillars of the MASLD model of care, including screening, risk stratification, and establishing a clinical care pathway for management, in addition to discussing the impact of nomenclature change on the proposed model of care.

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%

Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

El-Kassas,

Awad,

Elbadry

et al. 2024

Semin Liver Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…For a definitive diagnosis, liver biopsy is indicated [136,137]. However, in NAFLD patients, on this point, there is a controversy related to the already mentioned eventuality of HCC occurrence in the absence of a clinically/histologically demonstrated cirrhosis, thus raising a discussion on what type of patient with NAFLD and without cirrhosis should undergo a more intensive surveillance for HCC [138,139].…”

Section: General Management Strategies For Nafld Complications: Fibro...mentioning

confidence: 99%

From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention

Motta,

Masarone,

Torre

et al. 2023

Cancers

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) affects up to a quarter of the adult population in many developed and developing countries. This spectrum of liver disease ranges from simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis. The incidence of NASH is projected to increase by up to 56% over the next 10 years. There is growing epidemiological evidence that NAFLD has become the fastest-growing cause of hepatocellular carcinoma (HCC) in industrialized countries. The annual incidence of HCC varies between patients with NASH cirrhosis and patients with noncirrhotic NAFLD. In this review, NAFLD/NASH-associated HCC will be described, including its epidemiology, risk factors promoting hepatocarcinogenesis, and management of HCC in patients with obesity and associated metabolic comorbidities, including preventive strategies and therapeutic approaches to address this growing problem.

show abstract

“…The epidemic of MAFLD has conferred a huge clinical burden on about one third of the global population [2]. As well as simple steatosis with histological signs of fat accumulation in hepatocytes only, the progressive forms also exist as hepatocyte injuries, apoptosis, necrosis, and inflammation cell infiltration, which eventually exacerbate liver failure, fibrosis, and hepatocellular carcinoma [3][4][5]. Although liver biopsy has been acknowledged as the gold standard for diagnosing MASLD, its limitations, such as procedural invasiveness, sampling variabilities, and other miscellaneous complications, hinder it from widespread use [6].…”

Section: Introductionmentioning

confidence: 99%

An Optimized Strategy Based on Conventional Ultrasound for Diagnosing Metabolic Dysfunction-Associated Steatotic Liver Disease

Feng,

Ye,

Deng

et al. 2023

Diagnostics

View full text Add to dashboard Cite

The inherent drawbacks of the conventional B-mode ultrasound for metabolic dysfunction-associated steatotic liver disease (MASLD) are poorly understood. We aimed to investigate the impact factors and optimize the screening performance of ultrasound in MASLD. In a prospective pilot cohort recruited from July 2020 to January 2022, subjects who had undergone magnetic resonance imaging-based proton density fat fraction (MRI-PDFF), ultrasound, and laboratory test-based assessments were included in the deprivation cohort. A validation cohort including 426 patients with liver histologic assessments from five medical centers in South China was also recruited. A total of 1489 Chinese subjects were enrolled in the deprivation cohort, and ultrasound misdiagnosed 62.2% of the non-MASLD patients and failed to detect 6.1% of the MASLD patients. The number of metabolic dysfunction components and the alanine aminotransferase (ALT) level were associated with a missed diagnosis by ultrasound (OR = 0.67, 95% CI 0.55–0.82 p < 0.001; OR = 0.50, 95% CI 0.31–0.79, p = 0.003, respectively). Compared with ultrasound alone, the new strategy based on ultrasound, in combination with measurements of the number of metabolic dysfunction components and ALT and uric acid levels, significantly improved the AUROC both in the research cohort and the validation cohort (0.66 vs. 0.84, 0.83 vs. 0.92, respectively). The number of metabolic dysfunction components and ALT and uric acid levels improved the screening efficacy of ultrasound for MASLD.

show abstract

Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis

Cited by 9 publications

References 74 publications

Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention

An Optimized Strategy Based on Conventional Ultrasound for Diagnosing Metabolic Dysfunction-Associated Steatotic Liver Disease

Contact Info

Product

Resources

About